Abstract Body

Nuclease-mediated gene editing holds great promise in the cure of HIV infection, but the efficacy of this approach in patients is unclear. We have targeted the CCR5 locus in hematopoietic stem cells (HSCs) and assessed engraftment following autologous transplant in the pigtailed macaque. CCR5 disruption in this model should directly protect against infection with simian/human immunodeficiency virus (SHIV). We are evaluating the extent to which CCR5-disrupted cell progeny impact SHIV infection in naïve animals, and viral reservoirs in previously infected, combination antiretroviral therapy (cART)-suppressed animals.

Animals are challenged with CCR5-tropic, HIV enveloped SHIV, and suppressed by three-drug cART following viral set point. Zinc Finger Nucleases (ZFNs) are used to disrupt CCR5 in autologous HSCs; these stem cells and their progeny are subsequently measured ex vivo and in vivo. In previously infected and suppressed animals, assays are conducted to measure the size of the latent SHIV reservoir before and after transplant.

In SHIV-naïve animals, we observe approximately 5% steady state bulk disruption of CCR5 in vivo, which persists following SHIV challenge. This approach is equally feasible in SHIV-infected, cART-suppressed animals. Virus-dependent selection for CCR5-disrupted HSC progeny is observed, namely in memory T-cell subsets. Viral reservoir assays demonstrate that sites of viral persistence are present in cART-suppressed animals, and are impacted by the transplant procedure.

We have built on our unprecedented demonstration of successful long-term engraftment of CCR5 gene-edited HSCs in vivo by showing that these cells can undergo virus-dependent positive selection. We are currently developing gene-editing approaches to enrich for CCR5-edited cells without the need for ongoing viral replication, using adeno-associated virus (AAV) to knock in a chemoselection marker at the disrupted CCR5 locus. This should allow for significant enrichment of infection-resistant cells in vivo under the cover of ongoing cART. These results have important implications for cART-independent control of viremia in HIV+ in patients, and should be a promising component of combinatorial HIV cure strategies.